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Summary 
The cytokine TWEAK and its cognate receptor Fn14 are members of the 
TNF/TNFR Superfamily and are upregulated in tumors. We found that Fn14, 
when expressed in tumors, causes cachexia, and that antibodies against Fn14 
dramatically extended lifespan by inhibiting tumor-induced weight loss while 
having only moderate inhibitory effects on tumor growth. Anti-Fn14 antibodies 
prevented tumor-induced inflammation and loss of fat and muscle mass. Fn14 
signaling in the tumor, rather than in the environment, is responsible for 
inducing this cachexia because tumors in Fn14- and TWEAK-deficient hosts 
developed cachexia that was comparable to that of wildtype mice. These results 
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extend the role of Fn14 in wound repair and muscle development to involvement 
in the aetiology of cachexia and indicate that Fn14 antibodies may be a 
promising approach to treat cachexia, thereby extending lifespan and improving 
quality of life for cancer patients. 
 
Introduction  
 
TWEAK (Tumor Necrosis Factor TNF Superfamily member 12) and its cognate 
receptor Fn14 (TNFRSF12A) have been shown to play multiple roles in the 
process of wound repair and can promote angiogenesis, proliferation, migration, 
apoptosis and inflammation (Burkly et al., 2011; Campbell et al., 2004; Vince 
and Silke, 2006a; Winkles, 2008). Consistent with such a role, Fn14 expression 
is strongly increased following wounding (Wiley et al., 2001). It has been 
suggested that tumors resemble "wounds that do not heal" (Dvorak, 1986) and in 
line with this, Fn14 expression is also increased in solid tumors (Culp et al., 
2010; Wiley et al., 2001). TWEAK/Fn14 signaling therefore contributes to 
carcinogenesis and targeting this pathway with monoclonal antibodies can 
inhibit tumor growth (Culp et al., 2010; Winkles, 2008). 
 
TWEAK activates both canonical and non-canonical NF-κB signaling pathways 
(Salzmann et al., 2013; Varfolomeev et al., 2007; Varfolomeev et al., 2012; 
Vince et al., 2008a), increases expression of genes associated with inflammation 
and fibrosis in myotubes (Panguluri et al., 2010) and promotes myofiber atrophy. 
In vivo studies using TWEAK transgenic and TWEAK or Fn14 knock-out mice 
support the idea that regulating myogenesis and muscle repair are physiological 
functions of the TWEAK/Fn14 signaling axis (Tajrishi et al., 2014). For 
example, transgenic overexpression of TWEAK in skeletal muscle leads to 
muscle atrophy in mice (Mittal et al., 2010a; Mittal et al., 2010b) while 
TWEAK-deficient mice have improved regeneration of skeletal muscle after 
injury (Girgenrath et al., 2006; Mittal et al., 2010a; Mittal et al., 2010b).  
 
Cachexia is a complex disease, best described as a metabolic disorder that 
includes progressive muscle wasting with or without the loss of fat stores. It 
frequently presents in the terminal stages of many chronic illnesses including 
cancer (Tisdale, 2010). Cachexia may be present in 50-80% of patients with solid 
tumors (Dewys et al. 1980; Laviano et al., 2005; Walsh et al. 2000). Although 
cachexia reduces patient survival and response to chemotherapy, and may 
account for ~25% of all cancer deaths (Warren, 1932), the molecular 
mechanisms are still poorly understood and there are currently no FDA approved 
drugs for cachexia. Attempts to cure cachexia by increasing appetite or nutrition 
have so far proven unsuccessful in clinical trials. However, it has been suggested 
that interventions for cachexia could potenitally be developed by targeting 
inflammatory processes that occur in concert with the wasting and metabolic 
imbalance that characterises the cachectic diagnosis (Muscaritoli et al., 2010). 
 
Inflammatory cytokines that have been suggested to play a role in cachexia 
include TNF, Interleukin-1 (IL-1), IL-6 and Interferon- (Argilés et al., 2009; 
Ohnuma and Holland, 2009; Tisdale, 2009). Glucocorticoids may also contribute 
to cachexia by upregulating tumor-derived factors such as lipid-mobilizing 
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factor, which activates degradative pathways in adipose tissue leading to the 
breakdown of fat deposits and disrupted metabolic processes (Islam-Ali and 
Tisdale, 2001; McDevitt et al., 1995; Russell and Tisdale, 2005). Most recently, 
it has been shown that activation of the activin type-2 receptor ActRIIb (Zhou et 
al., 2010) by TGF- family ligands drives a cachectic phenotype in mice and the 
degradation of myofibrillar proteins through the ubiquitin-proteasome pathway. 
Excitingly, given the dearth of pharmacological targets for this devastating 
disease, recombinant decoy ActRIIb inhibited activation of this pathway and 
significantly increased survival and muscle mass of mice bearing cachexia-
inducing tumors (Zhou et al., 2010). Unfortunately decoy ActRIIb clinical trials 
in healthy adults and boys with Duchenne muscular dystrophy were stopped 
because of treatment-related bleeding issues and so have not been pursued for 
cachexia treatment. A modified version that has reduced Activin binding has 
however showed encouraging activity in promoting hematopoiesis in mice 
(Suragani et al., 2014). 
 
Because of the demonstrated involvement of TWEAK/Fn14 signaling in tumor 
progression, we hypothesised that an antagonistic monoclonal antibody targeting 
Fn14 would inhibit tumor growth (Vince and Silke, 2006; Winkles, 2008). We 
therefore developed and characterized three antagonist monoclonal antibodies 
against Fn14. Two of these antibodies showed variable ability to block tumor 
growth but were strikingly effective at preventing tumor-induced weight loss. 
We demonstrated that the tumor-induced loss of lean and fat mass is consistent 
with the development of cachexia and that our Fn14 antibodies were able to 
prevent and reverse tumor-induced cachexia in different tumor models. Our 
results support the hypothesis that inhibiting Fn14 signaling has therapeutic 
potential for cancer-induced cachexia.  
 
Results 
 
Monoclonal antibodies against Fn14 
To test the hypothesis that inhibition of Fn14 would limit tumor growth, we 
generated several antagonist monoclonal antibodies against Fn14 by inoculating 
wild type mice with recombinant human Fn14-Fc and generated hybridomas as 
previously described (Galfre and Milstein, 1981). The antibodies were positive 
when screened against a Mouse Embryonic Fibroblast (MEF) cell line stably 
expressing an inducible human Fn14 construct using flow cytometry. Three of 
these: 001, 002 and 004 are described here (Figure 1A). A commercially 
available anti-human Fn14, ITEM1 (Nakayama et al., 2003), also reacted with 
human Fn14 in a similar fashion (Figure 1A). ITEM1 and our three novel 
antibodies detected human Fn14 specifically by Western blot (Figure 1B). 
Human and mouse Fn14 are 92% identical in the extracellular domain, and 
consistent with this, two of the antibodies, 001 and 002 reacted against the 
uninduced MEF cell lines that express endogenous murine Fn14 (Figure 1A). 
Thus all of the antibodies specifically recognise human Fn14 and 001 and 002 
also cross-react with murine Fn14. 
 
Because members of the TNF Receptor Superfamily (TNFRSF) share some 
homology in their extra-cellular domain, if any proteins are cross reactive with 
our antibodies, members of the superfamily are the most likely candidates. 
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However many of these receptors are only expressed in specific hematopoietic 
lineages making it difficult to definitively rule out cross reactivity by screening 
cell lines. Therefore, a number of VSV- or HA-tagged TNFRSF members were 
over-expressed in HEK293T cells and reacted with either a VSV, HA, 001 or 
002 antibody. All TNFRSF receptors were expressed and readily detected by the 
VSV or HA antibody, however only Fn14 was detected by 001 and 002 
antibodies (Figure 1C). 
 
To address whether the Fn14 antibodies activated or blocked Fn14-dependent 
signaling, we used a HEK293T cell line, that expresses endogenous human 
Fn14, stably transduced with a lentiviral NF-B reporter vector (Vince et al., 
2008b; Figure 1D). The antibodies were unable to stimulate NF-κB, 
demonstrating that in this assay they are not Fn14 agonists (left column, Figure 
1D). Our antibodies, but not a control IgG antibody, did however block 
TWEAK/hFn14 induced NF-κB (Figure 1D). To functionally assess the ability 
of our antibodies to inhibit TWEAK/hFn14 signaling we used human 
rhabdomyosarcoma Kym1 cells that are exquisitely sensitive to cell death 
induced by TWEAK (Schneider et al., 1999; Vince et al., 2008a). We co-
incubated Kym1 cells with or without TWEAK (at 5, 50 or 200 ng/ml) and 
monoclonal antibodies at a concentration of 1 µg/ml for 24 hours. All adherent 
and floating cells were harvested and stained with Propidium Iodide (PI) and the 
percentage of dead, PI-positive cells was determined by flow cytometry. Both 
antibodies 001 and 002 were able to inhibit TWEAK-induced death of Kym1 
cells, however antibody 004 was ineffective in this assay (Figure 1E). 
 
To define the epitope that the antibodies bound to, the structure of the 
extracellular domain of Fn14 was assessed (Pellegrini et al., 2013; Brown et al., 
2006) and two ‘subdomains’ were generated as peptides. Antibody binding to 
these sub-domains was assessed by quantitative ELISA. All antibodies bound 
efficiently and specifically to sub-domain 2 but not to sub-domain 1 (Figure 1F 
and S1A). A series of point mutants of extracellular domain constructs 
representing human Fn14 and mouse Fn14 were generated for expression and 
purification from E. coli. These mutations were chosen based on mouse-human 
differences and also residues described to be important for binding of other 
known Fn14 antibodies. Consistent with the results from the other assays, 001 
and 002 bound human and mouse Fn14 extracellular domains equally well, 
while ITEM1 bound better to human Fn14 than to mouse (Figure S1B). 
Furthermore, 001 and 002 bound point mutants of human Fn14 identically while 
ITEM1 and 004 had a distinct epitope binding profile (Figure S1B, D, E & F). In 
summary, these results demonstrate that 001 and 002 antibodies bound 
specifically to a defined extracellular epitope on the Fn14 receptor and can 
inhibit Fn14/TWEAK signaling. Antibody 001 is an IgG2b and 002 is an IgG1. 
Both recognize human and murine Fn14 and efficiently inhibit Fn14 signaling. 
 
Fn14 antibodies increase survival of Colon-26 tumor-bearing mice 
To test our hypothesis that an antagonistic Fn14 antibody could inhibit tumor 
growth we used the Lewis Lung Carcinoma (LLC) and Colon-26 (C-26) tumor 
cell lines commonly used in allograft studies that respectively express low and 
high Fn14 levels (Figure 2A). In the C-26 tumor model, groups of five 
immunocompetent CD2F1 mice were inoculated with 1106 C-26 tumor cells, 
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then treated or not with the 002 antibody on days 5, 12, 15 and 20 post-
inoculation. Tumor growth displayed some inter-individual heterogeneity, but 
growth was on average slightly slower in the treated compared to the untreated 
mice (Figure 2B). However the survival of the treated mice was dramatically 
extended (Figure 2C). While the tumors in untreated and treated animals were 
comparable in size over the 18 days post inoculation, untreated mice lost weight 
rapidly from day 11 onwards while treated mice maintained weight and condition 
during this period (Figure 2D). Maintenance of weight in a pair fed control group 
showed that the decrease in body mass in the untreated C-26 tumor mice was not 
due to differences in food intake (Figure 2D). 
 
Fn14 antibodies block Colon-26 tumor-induced cachexia 
Both the LLC and C-26 cell lines have been shown to induce cachexia in mice, 
although the LLC model is generally milder in disease severity (Murphy et al., 
2012; Zhou et al., 2010). Hallmarks of this disease include loss of lean body 
mass, loss of muscle function and systemic inflammation (Murphy et al., 2012). 
This is in stark contrast to starvation where lean body mass and muscle function 
are preserved in the short term. To test whether the anti-Fn14 antibody inhibited 
cachexia in C-26 tumor bearing mice, we treated 10 mice with either anti-Fn14 
or an isotype control IgG (IgG1) dosed on days 8, 12 and 16 post tumor 
inoculation and sacrificed them at day 22. For pragmatic reasons these 
experiments were performed in different labs with a different source of C-26 
tumor cell line. As observed before in the absence of therapy, C-26 tumor mice 
began to lose weight around 11 days post tumor inoculation, and although there 
was a slightly slower decline in weight using this alternative source of C-26 
cells, anti-Fn14-treated mice retained body weight (Figure 3A). In a separate 
experiment, untreated C-26 tumor bearing mice were compared to a non-tumor 
“PBS” group that were injected with PBS in place of C-26 cells and then pair-
fed against the C-26 group (blue and grey lines, respectively). On comparison, 
the anti-Fn14 treated mice actually had higher relative body mass than the pair-
fed PBS controls by the end of the experiment (Figure 3A). As before, tumors in 
the antibody-treated mice grew slower than in control mice but weight loss was 
already well advanced by day 17 when tumor size differences were negligible, 
indicating that the anti-tumor effect of the antibody was not the reason for the 
reduction in cachexia (Figure S2, Figure 3A). The preservation of weight in the 
anti-Fn14-treated mice was even more apparent when the weights of the mice 
without tumors were measured (Figure 3B). Furthermore, the mass of several 
muscles (soleus, extensor digitorum longus [EDL], plantaris, tibialis anterior 
[TA], gastrocnemius and quadriceps) in anti-Fn14-treated mice was significantly 
spared compared to the untreated and control IgG-treated mice such that muscle 
mass was similar to PBS controls (Figure 3C, D). Heart mass was also 
significantly spared in anti-Fn14-treated mice and similar to non-tumor-bearing, 
PBS-injected control (Figure 3D). Not only did anti-Fn14 treatment prevent loss 
of epididymal fat mass in C-26 tumor-bearing mice compared to control-treated 
and untreated mice but fat mass was even increased above controls with no 
tumors (Figure 3E). Consistent with the preservation of muscle mass, peak grip 
strength in living mice at day 21 was increased in anti-Fn14-treated mice 
compared to untreated and control IgG treated mice (Figure 3F). Peak twitch 
force (Figure 3G), peak tetanic force (Figure 3H) and tetanic force over a range 
of stimulation frequencies (Figure 3I) of TA muscles assessed in situ was also 
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significantly higher in anti-Fn14-treated animals compared to untreated and 
control-treated mice, and reached forces similar to those obtained in non-tumor 
controls. After determining peak tetanic force, muscles were subjected to a four 
minute intermittent stimulation protocol to induce muscle fatigue. Again, the TA 
muscles of anti-Fn14-treated mice produced higher forces throughout most of 
the fatiguing stimulation protocol than the control and untreated mice (Figure 
3J). 
 
These results strongly suggested that C-26 tumor mice treated with anti-Fn14 
antibody were resistant to cachexia. To investigate this observation at the 
cellular level, TA muscle sections were stained with hematoxylin and eosin 
(H&E), revealing a larger fiber size in anti-Fn14-treated mice compared with the 
untreated and control treated mice and similar to PBS controls (Figure 4A). 
Sections stained with anti-laminin confirmed the increase in muscle fiber size in 
anti-Fn14-treated mice (Figure 4B), and co-staining with a myosin IIa specific 
antibody (N2.261) to identify type IIa and type IIx/b fibers (non-N2.261 reacting 
fibers) revealed that the cross-sectional area of both fast, oxidative type IIa fibers 
and fast, glycolytic type IIx/b fibers was increased with anti-Fn14 (Figure 4C, 
D). The proportion of type IIa and type IIx/b fibers was similar between treated 
and untreated groups (Figure 4D), as was muscle fiber oxidative capacity as 
assessed by reacting for succinate dehydrogenase activity (SDH, Figure 4C, E). 
These results show that the protection of muscle mass and strength with anti-
Fn14 treatment was due to the protection of individual muscle fibers and not a 
shift in muscle fiber type composition. 
  
TWEAK signaling has been shown to induce muscle atrophy through activation 
of the ubiquitin proteasome and inhibition of the Akt/p70S6K pathway (Dogra et 
al., 2007). We therefore investigated the effect of anti-Fn14 treatment on the 
mRNA expression of the ubiquitin ligases MuRF-1 and atrogin-1. Consistent 
with the increase in muscle mass and fiber size in anti-Fn14-treated mice, 
MuRF-1 and atrogin-1 mRNA expression was significantly reduced in the TA 
muscle of anti-Fn14-treated tumor-bearing mice compared with untreated and 
IgG-treated mice and the levels in the non-tumor-bearing mice (Figure 4F). In 
addition to the loss of muscle, mRNA expression of the inflammatory cytokines 
IL-6 and TNF were significantly higher in TA muscles from C-26 control and 
IgG-treated mice compared to anti-Fn14-treated mice, indicating that anti-Fn14 
protects mice from muscle loss and also reduces the cachectic inflammatory 
phenotype (Figure 4G). 
 
To test whether anti-Fn14 antibody inhibited cachexia in mildly cachectic LLC 
tumor-bearing mice, we treated mice with either anti-Fn14 (002) or an isotype 
control IgG dosed on days 7, 14, 21 and 28 post tumor inoculation and sacrificed 
them at day 35. Antibody treatment slowed tumor growth (Figure S3A, B) and 
although it had no significant effect on body mass in the PBS groups (Figure 
S3C), it slightly increased body mass in LLC tumor-bearing mice (Figure S3D).  
 
Fn14-expressing tumors cause severe cachexia in mice 
Collectively, results obtained with anti-Fn14 antibody 002 suggested that Fn14 
signaling was sufficient to promote cancer-induced cachexia. To test this 
hypothesis, fibroblast cell lines derived from C57BL/6 embryos and transformed 
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with a H-Ras V12 oncogene were infected with a hFn14-expressing lentivirus. 
As a control, we infected the same parental cell line with a lentivirus expressing 
only the extracellular domain of hFn14 fused to a GPI anchor. Both hFn14 and 
control cell lines formed tumors when injected into mice and initially grew at 
similar rates (Figure 5A). Eight days post inoculation, mice bearing hFn14 
expressing tumors, but not the control tumors, suffered rapid weight loss and 
their overall health deteriorated quickly (Figure 5B). Post mortem analysis of 
these mice revealed increased vasculature (Figure 5C) and tumor invasive 
capacity (Figure 5D) in the hFn14-expressing tumors when compared with 
controls. 
 
Fn14 antibodies block Fn14-induced cachexia in mice 
As further confirmation of our hypothesis that blocking Fn14 signaling prevents 
cachexia we used the monoclonal 001 in the following experiments. Antibody 
001 has an Fn14 binding profile and ability to block Fn14 signaling that is 
almost identical to antibody 002 but has some differences (total of 15 amino acid 
differences across the 6 CDR regions in the heavy and light chain sequences and 
is a different isotype [IgG2b]). Mice were inoculated with MEF tumor cells 
expressing Fn14 or not and on the first day of marked weight loss (day 6) were 
treated with antibody 001 or IgG2b isotype control. The experiment was run for 
11 days when a clear decline in weight and condition was seen in the IgG2b-
treated controls. As before, hFn14 expressing tumors caused a loss of body mass 
(Figure 6A), and a single treatment with anti-human Fn14, but not the isotype 
control antibody, substantially prevented this loss (Figure 6A-C), even though 
tumor mass and volume was not significantly different between groups (Figure 
S4). Fn14 tumors caused a significant decrease in mass of the TA and plantaris 
muscles and a trend for lower muscle mass of EDL, soleus, gastrocnemius and 
quadriceps (P<0.09, Figure 6C). There was no significant change in heart mass 
in Fn14 tumor bearing mice (Figure 6D) but a significant decrease in 
subscapular fat mass (Figure 6E). Remarkably, the loss of muscle and fat mass 
in hFn14-expressing tumor mice was reduced by a single injection of anti-human 
Fn14 antibody (Figure 6C & E). 
 
The contractile properties of muscles in live mice were assessed on day 11 but 
there were no significant differences between groups in grip strength (data not 
shown), and in anesthetized mice there were no differences in peak twitch force 
(data not shown), peak tetanic force and specific (normalized) force of TA 
muscles in situ (Figure 6F). However, tetanic force over a range of stimulation 
frequencies (10-300 Hz) was lower in TA muscles from mice with hFn14 tumors 
than mice bearing control tumors and this reduction in force was prevented by 
treatment with anti-Fn14 (Figure 6F, left panel). Anti-Fn14 also increased 
relative force production during and after a 4-minute intermittent fatiguing 
stimulation protocol, indicating reduced muscle fatigability following anti-
human Fn14 treatment (Figure 6G). 
 
TA muscle sections were stained with H&E, anti-laminin, and anti-myosin IIa 
(N2.261) antibodies to examine the effect of Fn14 tumor expression on muscle 
fiber architecture and fiber cross-sectional area (Figure 6H). Consistent with the 
C-26 experiments, hFn14 tumors caused a significant decrease in muscle fiber 
cross-sectional area (Figure 6I), which was due to decreases in size of both type 
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IIa and type IIx/b fibers (Figure 6J). Remarkably, a single injection of anti-Fn14 
prevented the decrease in muscle fiber size (Figure 6H & I). It was also 
interesting to note the greater space between individual fibres in hFn14 tumor-
bearing mice that was absent after anti-Fn14 treatment (Figure 6H). Despite 
improvements in muscle fatigability, anti-Fn14 did not cause a shift in fiber type 
proportions (Figure 6H & J) or muscle fiber oxidative capacity as assessed by 
SDH reaction intensity (Figure 6H & J). Assessment of mRNA levels of IL-6, an 
inflammatory marker of cachexia in TA muscle, also revealed that similar to the 
C-26 tumor-bearing mice, hFn14 tumors caused a significant increase in IL-6 
expression in TA muscles compared to control tumors and anti-Fn14 treatment 
blocked this increase (Figure 6K). 
 
Not all Fn14 antibodies are anti-cachectic 
Given the success of two different Fn14 antibodies (001 and 002) in blocking 
weight loss and extending survival in tumor-bearing mice, we asked whether any 
Fn14 antibody would be efficacious against the symptoms of cachexia. We 
therefore assessed our third antagonistic antibody, 004, along with a 
commercially available antibody, ITEM1. 004 is specific to human Fn14 and 
unlike either 001 or 002 did not cross react with murine Fn14. ITEM1, unlike 
either 001, 002 or 004, did not antagonise TWEAK/Fn14 signaling in the NF-κB 
reporter assay (Figure 1D, Figure S5). Human Fn14 expressing MEF tumors 
were established in mice and a single dose of antibody was administered at day 
7, just prior to noticeable weight loss, to randomized groups of mice. Consistent 
with the preceding experiments, 001 and 002 prevented weight loss induced by 
Fn14 tumors (Figure 7A) and improved survival (Figure 7B) yet all groups of 
mice had similar tumor sizes over the critical differential survival period (Figure 
7C). However 004 and ITEM1 were unable to prevent Fn14 tumor-induced 
weight loss or improve survival. These observations were also confirmed in an 
independent study where antibody was administered after the onset of weight 
loss (Figure S6). These results suggest that neither the ability to bind human 
Fn14 nor antagonistic properties of an antibody to human Fn14 are sufficient to 
predict its ability to inhibit cachexia.  
 
Host TWEAK and Fn14 are not involved in propagating cachexia  
TWEAK/Fn14 signalling has been reported to play a role in muscle atrophy 
(Tajrishi et al., 2014). To determine whether tumors were a direct or indirect 
source of TWEAK and thereby promoted Fn14-dependent muscle loss, we 
established Fn14 tumors in Fn14- and Tweak-deficient mice. Mice were 
inoculated with MEF Fn14 tumor cells on day 1 and body weight and tumor size 
were monitored (Figure 8). Body, tumor, muscle (TA, Quad, heart) and 
epididymal fat weight (male mice) were assessed (Figure 8A, B & C). There 
were no differences in the onset, severity or timing of cachexia in either strain of 
knock-out mice suggesting that neither host (muscle or other tissue) Fn14 nor 
TWEAK play a causative role in the muscle atrophy or fat loss induced by this 
tumor. The starting weights are standardised for ease of visualisation of the data, 
but the average starting weights of wild type (29.7g), Fn14-/- (28.5g) and   
Tweak-/- (26.4g) mice were approximately equivalent. 
 
The monoclonal anti-TWEAK antibody MTW-1 has been shown to be effective 
in reducing collagen induced arthritis and blocking macrophages from 
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infiltrating tumors in vivo (Kaduka et al., 2005; Kamata et al., 2006). In vitro, 
MTW-1, but not an isotype control antibody, blocked TWEAK induced NF-B 
in our reporter assay (Figure 8D). To test the ability of MTW-1 to prevent MEF 
Fn14-induced cachexia, wildtype mice with tumors were treated with this 
antibody or an isotype control antibody (Rat IgG) on day 7 and body weight was 
monitored over time. In contrast to the anti-Fn14 antibody treatment, MTW-1 
(anti-TWEAK) had no effect on the rapid induction of cachexia by the MEF 
Fn14 tumor (Figure 8E). Together these results show that neither tumoral nor 
humoral sources of TWEAK drive cachexia in this model. 
 
Using a next generation sequence approach to survey gene expression, we 
recently found that muscle wasting induced by local transduction of mouse limb 
muscles with a recombinant adeno-associated virus based vector expressing 
activin A (AAV:ActA) was associated with up-regulation of Fn14 transcription 
(Chen et al., 2014). Abundance of Fn14 protein, as determined by Western blot, 
was increased approximately 10-fold in muscles administered the activin-
expressing vector, compared with contralateral limb muscles administered a 
control vector (Chen et al., 2014). Because local over-expression of activin A 
induced marked muscle wasting, we asked whether induction of Fn14 was 
causative of muscle wasting in activin A over expressing muscle. To test this, we 
transduced the right tibialis anterior hind-limb muscles of C57BL/6 mice with 
our aforementioned AAV vector expressing activin A, and administered a 
control AAV vector in the left TA muscle. Mice were treated with antibody 001, 
002 or an IgG control antibody commencing four days after administration of 
AAV vectors, and for a total of six injections per mouse prior to assessment at 
the experimental endpoint four weeks after vector administration.  As we 
previously reported, increased local expression of activin A caused muscle 
wasting (Figure 8F, G), however, neither the 001 nor 002 Fn14 antibodies 
blocked activin A-induced muscle loss. These results indicate that while Fn14 is 
up-regulated in muscle during activin A-induced muscle wasting, it is not 
causative of the observed loss of muscle mass. 
 
Given the dramatic procachectic effects of Fn14-expressing tumors in mice, it 
was of interest to see if there is any correlative data that might indicate whether 
the same scenario pertains in human cancers. We examined the mRNA 
expression and clinical data for a range of cancers in the GDAC (Genome Data 
Analysis Centre) Firehose at the Broad Institute 
(https://confluence.broadinstitute.org/dosplay/GDAC/home). For cancers where 
sufficient sample sizes exist, there is a positive correlation for the expression of 
Fn14 with proinflamatory cytokines in human cancers (Figure S7). In breast, 
head and neck, lung, colorectal and stomach cancer, IL-1α (Figure S7A), IL-1ß 
(Figure S7B), IL-6 (Figure S7C), IL-8 (Figure S7D) and TNF (Figure S7E) all 
correlate positively with Fn14 expression. Correlation coefficients that are 
statistically significant at Benjamini and Hochberg adjusted P-value <0.05 are 
highlighted (*; Benjamini, 1995) and underscore that for the largest sample sizes 
(Breast and Lung) there is a strong statistical correlation between Fn14 and 
inflammatory cytokine expression by the tumors (Figure S7F). 
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Discussion 
 
We developed antibodies to Fn14 to specifically block Fn14 signaling in order to 
reduce tumor growth and development. Our antibodies were specific and were 
selected on the basis that they inhibited TWEAK-Fn14 induced NF-B signaling 
and cell death. We initiated studies in vivo thinking therefore that these 
antagonistic antibodies might impede tumor growth (Wiley et al., 2001; 
Winkles, 2008; Lassen et al., 2015; Yin et al., 2013). Our antibodies however 
had incomplete and tumor specific effects on tumor growth; LLC tumor growth 
was inhibited most whereas Ras transformed MEF tumor growth was affected 
very little. 
 
In the C-26 model there was an intermediate effect on tumor growth of our 
antibodies however the most remarkable effect of the antibodies was to 
dramatically prevent loss of weight, ameliorate the general condition and 
prolong survival. Tumors can cause anorexia, or suppress appetite (Maccio et al., 
2012), however in this case loss of weight was not due to a tumor effect on 
feeding because pair fed controls retained body mass. 
 
Cachexia is a poorly understood disease and a co-morbidity with many 
conditions of chronic illness in addition to cancer. The defining hallmark of 
cachexia is loss of lean muscle mass and in some cases loss of fat. Our poor 
understanding of the signaling pathways causing cachexia has meant that current 
cachexia therapies generally target the symptoms rather than the cause of the 
disease. For example, Ghrelin, a peptide hormone originally isolated from the 
stomach that stimulates appetite, has been used in cachectic patients to combat 
loss of body mass (Maccio et al., 2012). However while clinical trials with 
Ghrelin show some promise it is ultimately ineffective because it does not 
address the cause of the disease. 
 
We therefore investigated the possibility that TWEAK/Fn14 signaling might 
contribute to cachexia. In our experiments, untreated and control-treated tumor-
bearing mice lost significant muscle mass from all of the major skeletal muscles 
and this loss was prevented by treatment with anti-Fn14. Furthermore, muscle 
function was also retained in the antibody-treated mice, along with fat stores and 
a decrease in inflammatory markers within target tissue was also observed.  
 
We had specifically chosen antibodies to Fn14 that are able to antagonize the 
action of TWEAK, in line with the hypothesis that Fn14-dependant cachexia is 
caused by an activation of signaling through Fn14. Although in vitro our 
antibodies could function as antagonists, a question that remains to be tested is 
whether they act as antagonists in vivo. We cannot rule out that in vivo these 
anti-cachectic antibodies are operating via Fc dependant multimerisation 
pathways and in vitro studies have shown the potential of cross-linked Fc 
domains to reveal agonistic activity (data not shown). This is a common and 
often desirable feature of antibodies and has been demonstrated for other Fn14 
antibodies (Culp et al., 2010; Salzmann et al., 2013). 
 
In addition to its effects on angiogenesis, TWEAK/Fn14 signaling has been 
linked to inhibiting myoblast to muscle differentiation (Dogra et al., 2006; 
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Girgenrath et al., 2006) and promoting myoblast proliferation. While Tweak 
(Tnfsf12) and Fn14 knock-out mice develop normally without any obvious 
difference in body or muscle mass, Tweak deficient mice lost less muscle mass 
following injury than wild type mice (Mittal et al., 2010a). This implies that 
TWEAK/Fn14 does not play a role in the normal development of muscle but 
may, in pathological scenarios, promote muscle loss directly. Consistent with 
this, TWEAK transgenic mice are smaller and have reduced muscle mass, 
reduced muscle fiber cross sectional area, and increased markers of ubiquitin 
proteasome activation (Dogra et al., 2007; Mittal et al., 2010a). Combined with 
the ability of our Fn14 antibody to inhibit cachexia, these observations naturally 
led to the hypothesis that TWEAK is the factor that drives muscle wasting in 
cancer induced cachexia. However the MEF tumors induced cachexia in both 
Fn14-/- or Tweak-/- mice which is inconsistent with this hypothesis. In addition to 
its effect on muscle, TWEAK has been shown to be required for liver 
regeneration following partial hepatectomy (Jakubowski et al., 2005; Karaca et 
al., 2014). Together these reports suggest that physiological levels of TWEAK 
contribute to regeneration of injured tissues, but that supraphysiological levels 
can promote damage, but that neither paradigm is relevant to cancer induced 
cachexia. 
 
Consistent with this concept, we showed that cachectic mice treated with a 
TWEAK-blocking antibody still developed cachexia. These results argue against 
the possibility that tumor-derived TWEAK is the causative factor in cancer 
cachexia and raise the question of the nature of the soluble factor produced by 
the tumor. Potential candidates for such signaling molecules could be activins or 
myostatin because cachexia induced by C-26 tumors was prevented by a decoy 
activin receptor (ActRIIb) that inhibits activin/myostatin signalling (Zhou et al., 
2010). Interestingly, although muscle wasting caused by C-26 tumors was 
successfully prevented by the ActRIIb decoy receptor, fat loss, another feature of 
cachexia, was unaffected (Zhou et al., 2010). In contrast anti-Fn14 treatment of 
C-26 cachectic animals prevented tumor induced inflammation, fat loss and 
reduction in muscle mass and function. Minimally we can conclude that if 
activin functions downstream of Fn14 to induce cachexia it is only one of the 
components produced by Fn14 tumors. 
 
Intriguingly, activin A over expression in muscle promotes up regulation of 
Fn14 and muscle wasting, implying that Fn14 signalling works downstream of 
activin. However Fn14 antibodies did not prevent activin A-induced muscle loss. 
These results further support the idea that, physiologically, Fn14 is up-regulated 
as part of a protective reparative response in muscle rather than to promote 
muscle loss. In tumors, however, there is an elevated expression of and constant 
activation of Fn14 that leads to pathological consequences in peripheral tissues. 
 
Phase I clinical trials using a soluble ActRIIb decoy receptor in Duchenne 
muscular dystrophy, begun in 2010, were terminated in 2011 because of 
increased incidence of nosebleeds, bleeding gums and dilated blood vessels in 
the skin. Because activin/myostatin play numerous roles throughout the body, it 
is, in hindsight, not surprising that blocking this pathway may lead to other side 
effects. Fn14 is therefore very attractive as a therapeutic target because it is not 
required for normal development. Its expression is strongly induced by growth 
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factors in vivo at sites of tissue injury, remodeling and in tumors (Culp et al., 
2010; Feng et al., 2000; Winkles, 2008). 
 
Cachexia in human cancer patients usually progresses slowly with an average 
loss of 5% body mass over 12 months, whereas cachectic mice lose weight very 
rapidly. In humans however, tumor mass as a proportion of body weight rarely 
exceeds 1%, while in murine tumor models the tumor can account for as much 
as 10% of the total mouse weight. Mice also have a different metabolism to 
humans. Despite the need to be cautious when translating results from mouse 
models to humans, it is noteworthy that in our experiments similar sized tumors 
caused very different cachectic effects. This demonstrates that cachexia is an 
active process with the tumor directly driving the loss of muscle and fat. 
 
Our analysis of the TCGA database revealed positive correlations between many 
inflammatory cytokines implicated in cancer cachexia and Fn14 transcripts in 
patients. However this data cannot directly address whether Fn14 expression 
plays a role in cachexia because databases are not annotated for cachexia 
presence or the contribution of cachexia to patient survival. Even though the 
incidence of cachexia in cancer patients has been estimated to be as high as 80% 
depending on the definition used (Wallengren et al., 2013), current databases are 
remarkably deficient concerning this important contributor to patient well being 
and survival. Our results therefore indicate a pressing and urgent need to 
generate patient sample data that acknowledges and records this important 
component. 
 
A therapy that directly targets cancer associated cachexia is desperately needed, 
because cachexia has been estimated to occur in a significant proportion of 
cancer patients before death and contributes to their inability to tolerate intensive 
treatment regimes (Argilés et al., 2009; Murphy and Lynch, 2009). Furthermore, 
cancer cachexia is associated with severe fatigue and systemic inflammation that 
directly affects quality of life, that may in turn negatively affect a patient's 
willingness to continue treatment (Maccio et al., 2012). The fact that anti-Fn14 
reagents are already well tolerated by cancer patients in clinical trials (Lam et 
al., 2011) argues strongly that interventions that inhibit Fn14 should now be 
tested for their efficacy in cancer patients presenting with hallmarks of cachexia. 
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Materials and Methods  
 
Monoclonal antibody generation - Immunisation of mice 
Purified recombinant Fn14-Fc (“TWEAK receptor”, tandem repeat, Tetramer; 
obtained from Amgen) was used for immunisations. Female Balb/c mice were 
immunised IP with 15 g of antigen in PBS emulsified in Complete Freund’s 
Adjuvant (Sigma) and incomplete Freund’s adjuvant (Sigma) for subsequent 
boosts. Boosts were performed at intervals of 4 weeks and a final intraperitoneal 
(IP) injection was given 3 days before spleens were removed and the spleen cells 
harvested. Test bleeds were taken 3-5 days post boost via the retro-orbital plexus 
and used for screening for the presence of an immune response. Blood collected 
from mice was allowed to clot at room temperature. The clot was removed by 
centrifugation and the serum collected and stored at -20C. 
 
Hybridoma production 
Hybridoma fusions were performed using ClonaCell®-HY Hybridoma Kit 
(Stemcell Technologies) according to the manufacturer's instructions. Briefly, 
spleen cells were isolated by spleen perfusion before fusion with mouse 
myeloma SP20. The selection and cloning steps were performed on 
methylcellulose-based semi-solid media in 96 well plates. The culture 
supernatants were screened by ELISA for IgG production and subsequently by 
flow cytometry for specificity to Fn14.  
 
Flow cytometry screening  
1×105 MEF H-Ras V12 Fn14 +/- induced with 100 nM 4-hydroxytamoxifen 
(4OHT) were used as a single population prior to staining. Cells were incubated 
at 4°C with samples or controls for 30 min in PBS, 2% BSA. Cells were washed 
and incubated with secondary antibody (AlexaFluor-647-conjugated goat anti-
mouse IgG, Invitrogen) for 30 min at 4°C in the dark. The BD FACSCanto II 
was used to perform flow cytometry according to the manufacturer's protocol and 
data analysis was performed using FlowJo. Experiments were representative of at 
least three independent experiments. 
 
Purification of antibody  
Approximately 2L of serum-free conditioned medium was collected per antibody 
over 5 days from 4 Triple Flasks 500cm2 (Thermo Scientific) of hybridomas 
cultured in Hybridoma Serum Free Media (Invitrogen) supplemented with 
penicillin-streptomycin. Medium was filtered through a 0.45 µm filter prior to 
purification. Antibodies were purified by affinity chromatography with a 5 ml 
column of Protein A Sepharose HiTrap MabSelect Xtra (GE Healthcare). The 
Protein A column was equilibrated with buffer containing 0.02 M sodium 
phosphate, 250 mM NaCl pH 6.85 and the antibodies were eluted with 0.1 M 
Glycine/HCl pH 3.0, followed by neutralization with 1 M Tris/HCl pH 9.0. The 
neutralized eluate was concentrated and the buffer was exchanged with PBS 
using a vivaspin 20 column (Sartorius). Endotoxin was removed from samples 
using Detoxi-Gel (Thermo Scientific) and measured with E-toxate kits (Sigma) 
according to manufacturer’s instructions or using the Charles River Endosafe 
PTS Portable Test System. Endotoxin levels of all final antibody preparations 
used for in vivo experiments were determined to be below the level of detection 
of the assay (less than 0.05 EU/mg of antibody). 
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Antibody isotyping 
Antibodies were isotyped using the BD
 
Cytometric Bead Array (CBA) Mouse 
Immunoglobulin Isotyping Kit according to the manufacturers instructions.  
 
Preparation of cell membranes for western blotting  
MEF H-Ras V12 and MEF H-Ras V12 Fn14 cells were grown to around 50% 
confluency then induced for 48 h by the addition of 4-OHT (100 nM).  Cells 
were harvested and washed with PBS, centrifuged and resuspended in 1 ml of 20 
mM Tris, pH 7.4 with 10 μg/ml final concentrations of DNAse1 and RNAseA. 
Cells were lysed and the genomic DNA sheared using a 27 G insulin syringe. 
Samples were centrifuged at 600 g at 4 °C for 3 min and the supernatant was 
collected and centrifuged at 20,000 g for 30 min at 4 °C. The pellet was 
resuspended in 80 μl of 1M Tris, 0.4% SDS. The final membrane preparations 
were stored at -20 °C. Proteins were separated on 4-12% Bis-Tris gel SDS 
PAGE. Western transfer to PVDF membrane was performed using a semi-dry 
apparatus. The PVDF filters were probed using antibodies 001 (1 μg/ml), 002 (1 
μg/ml), 004 (10 μg/ml) and ITEM1 (Biolegend; 5 μg/ml). HRP-conjugated 
secondary goat anti mouse antibody was used for detection.  
 
Flow cytometry of cell lines for Fn14 expression levels 
Colon-26 (C-26) and Lewis Lung Carcinoma (LLC) cells adapted for growth in 
0.5% fetal calf serum, were assessed for Fn14 expression levels. Cells were 
stained using commercially available anti-Fn14 antibody ITEM1 (5 μg/ml) and 
detected using an AlexaFluor-647 secondary antibody (10 μg/ml). Cells were 
resuspended in 1% BSA/PBS then assessed by flow cytometry on a BD FACS 
Canto II.  
 
Cloning of Fn14 and Fn14-GPI constructs for tumor cell lines 
The 4-hydroxytamoxifen (4OHT) inducible lentiviral infection system (Vince et 
al., 2007)  was used. The full length wildtype cDNA for human Fn14 
(NM_016639) was cloned into the lentiviral vector pF_UAS_Neo at BamH I and 
Nhe I. The control construct containing the cDNA for the extracellular region of 
Fn14 (Forward CGCGGATCCATGGCTCGGGGCTCGCTGCGC Reverse 
GCTGGTGGTCATCCAAAGCAGCCGGAAGGGGGCAGG) fused to the 
TrailR3 GPI anchor coding region (AF020502) was created by overlap PCR 
(Forward primer CGGCTGCTTTGGATGACCACCAGCCCGGGGACTCCT, 
Reverse primer CGCGCTAGCTTATCAAACAAACACAATCAGAAG) to 
create Fn14-GPI. Constructs were confirmed by DNA sequencing.    
 
MEF cell lines for in vivo tumor model (Fn14 and Fn14-GPI) 
SV40 immortalised mouse embryonic fibroblasts (MEFs) from wildtype C57 
Black 6 mice were transformed with human H-Ras V12 by retroviral infection. 
H-Ras V12 transformed cells were then infected with lentivirus for GEV16 and 
either Fn14 or Fn14-GPI. Cells were selected with appropriate antibiotics for a 
minimum of 2 weeks before flow cytometry screening was performed to confirm 
protein expression. The Fn14 expressing cell line was used in experiments 
described in Figure 5 or passaged once in mice prior to being used for all other 
experiments. 
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TNFRSF cross reactivity assessment 
HEK 293T cells were transiently transfected with DNA constructs coding for 
various TNFRSF members using Lipofectamine 2000. The TNFRSF coding 
regions included an N-terminal VSV or HA tag. 24 hours post tranfection, cells 
were harvested and lysed in RIPA buffer (150 mM NaCl, 0.1% SDS, 0.5% 
Sodium deoxycholate, 1% TritonX-100, 50 mM Tris-HCl pH 7.2) with added 
DNaseI (2 g/ml), RNaseA (2 g/ml) and protease inhibitors (Roche). Samples 
were prepared in SDS-PAGE sample buffer containing -mercapotethanol and 
proteins were separated by SDS-PAGE and after western transfer the expression 
of TNFRSF members were detected using either an anti-VSV antibody or anti-
HA. Membranes were also probed using 001 and 002 for antibody cross 
reactivity.  
 
HEK293T NF-B GFP assay 
HEK293T cells containing a stably integrated NF-B promoter followed by GFP 
open reading frame were used to test for functionally active antibodies (Vince et 
al., 2008a). Cells were incubated for 24 h in the presence or absence of purified 
recombinant Fc-TWEAK at a concentration of 50, 100 or 200 ng/ml. In addition, 
purified antibody (100 ng/ml or 1 g/ml) or controls were added. Cells were 
harvested and GFP fluorescence was measured by flow cytometry (BD FACS 
Canto II, Diva software). A minimum of 10,000 events per sample were 
recorded. Isotype controls were used at equivalent concentrations. ITEM1, 
IgG2b, IgG1, Anti-TWEAK (MTW-1) and Rat IgG1 control antibody were 
purchased from Biolegend. 
  
Kym1 cell death assay 
Kym1 cell death assays were performed (Vince et al., 2008b) as described for 
the HEK293T NF-B-GFP assay. Cells were incubated for 24 h in the presence 
or absence of Fc-TWEAK (5, 50 or 200 ng/ml), and purified antibodies (100 
ng/ml or 1 g/ml) or controls. Total cells were harvested and analysed by flow 
cytometry in the presence of Propidium Iodide (PI; Sigma P4170) at a 
concentration of 1 g/ml. Data was graphed as the percentage of cell death.  
 
Tumor cell lines and tumor studies 
Cell lines used included two independent sources of Colon-26 cells (C-26; Cell 
Line Services; Germany and kindly donated by Martha Belury, The Ohio State 
University, Columbus, OH), Lewis lung carcinoma (LLC; European Collection 
of Cell Cultures). Cells cultured in 10% DMEM (MEF cell lines and LLC) or 
10% RPMI (C-26) were grown to a confluency of 80% and then harvested using 
brief trypsinisation. Cells were centrifuged at 1,000 g for 7 min followed by 2 
washes in phosphate buffered saline (PBS). Cell viability was assessed using 
trypan blue.  
Mice were obtained from the Animal Resources Centre (Canning Vale, Western 
Australia) or Monash Animal Services (Monash, Victoria) and all experiments 
described throughout that involved the use of mice were approved by the Animal 
Ethics Committees of La Trobe University (AEC 13-52, 10-54, 11-37 & 10-
19B), The University of Melbourne (AEC 1112069) and the Alfred Medical 
Research and Education Precinct (AEC E/1289/2012/B) and conducted in 
accordance with the Australian code of practice for the care and use of animals 
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for scientific purposes as stipulated by the National Health and Medical Research 
Council (Australia). Mice were housed under a 12:12-hour light-dark cycle. 
Mouse weights, the formation of solid tumors and general clinical health 
observations were taken daily throughout the duration of experiments. Tumor 
measurements were made using digital calipers and the tumor volume was 
calculated using the formula (lengthwidth2)/2. Water was available ad libitum 
and both water and standard laboratory chow was provided, changed and 
monitored daily. Pair feeding was achieved by monitoring the food intake of the 
untreated group each 24 h and then providing the pair-fed group with that 
amount of food for the following 24 h period. All antibodies administered to 
mice were purified in sterile, endotoxin free PBS. Isotype control IgG2b , isotype 
control IgG1 and ITEM1 were obtained from Biolegend.   
 
For MEF-Fn14 tumor studies, 11-12 weeks-old female C57BL/6 mice were used 
and for the C-26 studies, 11-12 weeks-old male CD2F1 (Balb/c x DBA) mice 
were used and 12-13 weeks-old male mice for the LLC tumor studies. 8-32 
weeks-old female and male Fn14 -/- mice and 12-21 weeks-old female and male 
TWEAK -/- mice were used (along side age matched control C57Bl/7 mice). 
Mice received a subcutaneous (s/c) injection of PBS alone or PBS containing 
5x105-5x106 cells on day 1 of the experiment using an insulin syringe. Cell lines 
included mouse embryonic fibroblasts stably infected with human Fn14 (MEF 
v12 Hras Fn14), an equivalent Fn14-GPI (MEF v12 Hras Fn14-GPI) or the 
untransfected MEF H-Ras V12 cells (MEF v12 Hras), mouse C-26 or mouse 
LLC. For antibody treatment experiments, mice were treated by IP injection of 0-
10 mg/kg purified antibody in 100 l of PBS on the days indicated in the figures.  
 
Muscle function analyses 
Grip strength test 
As described in detail previously (Murphy et al., 2012), whole body strength was 
assessed on day 2121 by means of a grip strength meter (Columbus Instruments, 
Columbus, OH). 
Assessment of functional properties of tibialis anterior muscles in situ 
On day 22 (C-26 study) or day 11 (MEF study), mice were anesthetized with 
sodium pentobarbitone (Nembutal; 60 mg/kg; Sigma-Aldrich) via IP injection. 
The methods for assessment of the contractile properties of the mouse tibialis 
anterior (TA) muscle in situ have been described previously (Murphy et al., 
2010). After examining the frequency-force relationship and determining peak 
tetanic force, muscles were subjected to a 4 min intermittent stimulation protocol 
to induce muscle fatigue. Muscles were maximally stimulated for 1 sec every 4 
sec for the duration of the fatigue protocol. Peak tetanic force was assessed at 5 
min and 10 min following cessation of the fatiguing stimulation protocol. At the 
conclusion of the contractile measurements in situ, the TA, extensor digitorum 
longus (EDL), soleus, plantaris, gastrocnemius and quadriceps muscles as well as 
the fat (epididymal for C-26 study, subscapular for MEF study) and heart were 
carefully excised, blotted on filter paper and weighed on an analytical balance. 
Mice were killed as a consequence of heart excision while still anesthetized 
deeply. 
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Skeletal muscle histology 
Serial sections (5 µm) were cut transversely through the TA muscle using a 
refrigerated (-20ºC) cryostat (CTI Cryostat; IEC, Needham Heights, MA). 
Sections were reacted with: laminin (#L9393, Sigma-Aldrich) for determination 
of mean myofiber cross-sectional area (CSA); succinate dehydrogenase (SDH) to 
determine activity of oxidative enzymes; and N2.261 (developed by Dr. Helen 
M. Blau, obtained from the Developmental Studies Hybridoma Bank developed 
under the auspices of the NICHD and maintained by The University of Iowa, 
Department of Biology, Iowa City, IA, USA) to assess the percentage of myosin 
IIa isoforms (Murphy et al., 2010). We have previously shown that mouse TA 
muscle contains a virtual absence of type I fibers (Murphy et al., 2011) so all 
non-N2.261 reacting fibers were assumed to represent type IIx/b fibers. Optical 
density of SDH was determined after 6 min of reactivity for all samples and 
sections were captured in full color using bright field light microscopy and 
analysed, as described previously (Murphy et al., 2010). Digital images were 
obtained using an upright microscope with camera (Axio Imager D1, Carl Zeiss, 
Wrek, Göttingen, Germany), controlled and quantified by AxioVision AC 
software (AxioVision AC Rel. 4.7.1, Carl Zeiss). 
 
Real-Time RT-PCR analyses.  
Total RNA was extracted from 10-20 mg of TA muscle using a commercially 
available kit according to the manufacturer’s instructions (PureLink RNA Mini 
Kit, Invitrogen). RNA concentration was determined spectrophotometrically at 
260 nm, and the samples stored at -80˚C. RNA was transcribed into cDNA using 
the Invitrogen SuperScriptTM VILO cDNA Synthesis Kit, and the resulting 
cDNA stored at -20˚C for subsequent analysis. Real-Time RT-PCR was 
performed as described previously (Murphy et al., 2010. Primer sequences for 
MuRF-1, atrogin-1, IL-6 and TNF- were as detailed previously (Murphy et al., 
2010). The content of single-stranded DNA (ssDNA) in each sample was 
determined using the Quanti-iT OliGreen ssDNA Assay Kit (Molecular Probes, 
Eugene, OR), as described previously (Murphy et al., 2010). Gene expression 
was quantified by normalizing the logarithmic cycle threshold (CT) value (2–CT) 
to the cDNA content of each sample to obtain the expression 2–CT/cDNA content 
(ng.ml-1). 
 
Activin A model of muscle atrophy 
AAV vectors carrying the Activin A expression cassette (or a control AAV, 
lacking the Activin cDNA) were injected at a dose of 1x109 vector genomes into 
the tibialis anterior (TA) hind-limb muscles of ~8 weeks-old male C57BL/6 mice 
placed under isoflurane anesthesia, as described previously (Chen et al., 2014). 
Following vector administration and recovery from anesthesia, mice were 
returned to their home cages, where they were randomly assigned to treatment 
cohorts receiving repeated administrations of either anti-Fn14 antibody or IgG 
control antibody. Antibody administration commenced 4 days after injection of 
vectors, and each mouse received a total of 6 antibody injections prior to the 
conclusion of experimental endpoint at 4 weeks after vector injection.  At the 
experimental endpoint, the mice were humanely killed via skilled cervical 
dislocation, and the TA muscles from both hind-limbs were excised to record 
mass and processed for storage at -80 °C.  
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Supplementary methods 
 
Epitope mapping using bacterially expressed protein 
Cloning of hFn14 and mFn14 constructs for bacterial expression 
Oligonucleotide primers, engineered with Nde I and Bam HI restriction sites, 
were designed, synthesized (Geneworks) and used to amplify the full-length 
extracellular domain of the human Fn14 (hFn14), the murine Fn14 (mFn14) 
extracellular domain and the human extracellular domain mutants (R56P, R56A, 
R56K, R58K) by PCR. Subsequent products were ligated into the vector pGEM-
4Z (Promega) cut with Sma I.  Plasmids from single clone were prepared and 
inserts were digested from the vector. Restricted inserts were then purified and 
inserted into pET-15b (Novagen) for expression in E. coli.  
 
Expression and purification of (His)6- proteins 
pET-15b derived vectors were transformed into Shuffle T7 Express E.coli  (New 
England BioLabs). Expression was induced by 1 mM IPTG at 30 °C for 4 h. 
Bacterial lysate was loaded onto a 1 ml Ni2+-nitrilotriacetic acid (Ni2+-NTA)-
agarose (Qiagen) column equilibrated with lysis buffer (20 mM Tris–HCl pH 
7.8, 300 mM NaCl, 20% (v/v) glycerol, 18 mM imidazole, 1 mM PMSF, 
Boehringer complete protease inhibitors. The column was first washed with 20 
ml of lysis buffer and recombinant proteins were eluted by 300 mM imidazole. 
Recombinant proteins were dialyzed and concentrated to 1 mg/ml in 25 mM 
HEPES-KOH (pH 7.4), 100 mM NaCl by a Centricon Centrifugal Filter Devices 
YM-10 (Millipore).  
 
Gel Filtration Chromatography 
(His)6- proteins were size-fractionated by gel filtration. Protein samples (1 ml) 
were loaded onto a HiLoad 16/60 Superdex 75 pg column (GE Healthcare) 
equilibrated with 25 mM HEPES-KOH pH 7.4, 100 mM NaCl at room 
temperature and were chromatographed at a flow rate of 1.5 ml/min on an 
ÄKTAxpress system (GE Healthcare). Elution profiles were detected at 280 nm 
and 1.5 ml fraction were collected. 
 
ELISA screening of monoclonal antibodies with purified (His)6- proteins 
The wells of Maxisorp immunoplates (Nunc) were coated overnight at 4 °C with 
2-fold serial dilutions of purified histidine tagged proteins (0.5 g/ml to 4 
ng/ml). Nonspecific protein binding sites were blocked with 1% milk protein in 
phosphate-buffered saline (PBS) for 1 h at room temperature. Plates were washed 
with PBST (PBS [10 mM Na-phosphate and 150 mM NaCl], 0.05 % Tween 20). 
Monoclonal antibodies diluted to 1 g/ml in PBST (PBS 0.05% Tween 20, pH 
7.4) + 0.1% milk protein were added and incubated at room temperature for 2 h 
in the coated plates. After washing with PBST, a 1:15000 dilution of peroxidase-
conjugated AffiniPure goat anti-mouse IgG (H+L) in PBST (Sigma) containing 
0.1% milk was added for 1 h at room temperature. ELISAs were developed using 
TMB substrate and the reaction was stopped using 2 M H2SO4 solution. 
Absorbance at 450 nm was quantified using a Spectramax absorbance 
spectrophotometer.  
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Epitope Mapping of Antibodies Using Synthetic Peptides 
Peptides representing sub-domains 1 (sub-domain1p), 2 and 3 of hFn14 (Figure 
S1A) and for the disulfide pair mutant (Cys4&5S; Figure S1F) were 
synthesized by GLBiochem Ltd. (Shanghai, China) and the cysteine residues for 
disulfide bonds were chosen as described in the solution structure of the cysteine-
rich domain in Fn14 by He et al., (2009). An additional lysine residue was added 
to the C-terminus in order to attach a biotin moiety and to enable the peptides to 
bind to neutravidin coated plates (Pre-blocked; Pierce). For these experiments, a 
control peptide with a biotin at the C-terminus was used as a negative control and 
isotype control antibodies were also used.  
The ELISA was performed essentially according to the manufacturer’s 
recommended protocol (Pierce). Briefly, peptide was coated onto wells (in 
duplicate) at 1-10 μg/ml for 2 h at room temperature. Wells were washed in 
PBS/0.05% Tween 20/0.1% BSA 3 times and dilutions of each antibody were 
added in wash buffer for 1 h with gentle agitation. After another three washes 
secondary anti-mouse HRP-conjugated (Chemicon) was added at 1/1000 dilution 
for 1 h shaking. Finally, after 4 further washes the plate was developed using 
TMB (3,3’,5,5’-tetramethylbenzidine) substrate (Pierce), and the reaction was 
stopped using 2M H2SO4 solution. Absorbance at 450 nM was quantified using a 
Spectromax absorbance spectrophotometer.   
 
Correlation analyses of Fn14 expression with cytokines and survival in TCGA 
(The Cancer Genome Atlas) human cancers 
The mRNA expression and clinical data for stomach, colorectal, lung, head and 
neck and breast cancers were downloaded from the GDAC (Genome Data 
Analysis Center) Firehose at the BROAD Institute 
(https://confluence.broadinstitute.org/display/GDAC/Home). 
The expression values are the normalized Log2 RSEM RNA-Sequencing data 
(Li et al., 2010). Pearson correlation was calculated for expression of Fn14 with 
expression of cytokine genes IL-1, IL-1, IL-6, IL-8 and TNF. The Benjamini 
& Hochberg (1995) adjusted P-value was calculated to measure the statistical 
significance of the observed correlations.   
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Figure Legends 
 
Figure 1. Antibodies to Fn14 antagonise TWEAK/Fn14 signalling 
(A) MEFs transformed with H-Ras V12 and expressing inducible human Fn14 
were stained with anti-Fn14 antibodies: 001, 002 or 004, commercial anti-Fn14 
antibody (ITEM1) or control non-specific IgG1 and IgG2b. Red histogram traces 
represent antibody staining. Overlaid black traces indicate staining with 
secondary antibody alone. 
(B) Fn14 antibodies bind specifically to Fn14. Lysates from H-Ras V12 MEFs 
expressing inducible human Fn14 minus (lane 1) or plus (lane 2) induction were 
separated on an SDS/PAGE gel, transferred to Nitrocellulose and probed with the 
indicated purified antibodies. 
(C) Fn14 antibodies are specific. HEK293T cells were transiently transfected 
with the indicated VSV or HA tagged TNF superfamily receptor constructs. 24 h 
post transfection, cells were harvested, and lysates separated by SDS/PAGE, 
transferred to PVDF and probed with the Fn14 antibodies 001 or 002 (1 μg/ml) 
anti-VSV or anti-HA antibodies, and detected using an HRP-conjugated 
secondary antibody. The arrows point to the band corresponding to the expressed 
protein. 
(D) Fn14 antibodies inhibit TWEAK/Fn14-induced signaling. HEK293T cells 
stably infected with a lentiviral NF-B GFP reporter were stimulated with or 
without 100 ng/ml of Fc-TWEAK (pink histograms). Cells were co-incubated 
with the indicated antibodies 001, 002, 004, control IgG +/- Fc-TWEAK for 24 
h. Cells were harvested and GFP fluorescence assessed by flow cytometry (grey 
histogram). 
(E) Fn14 antibodies inhibit TWEAK/Fn14 signaling. Kym1 cells were stimulated 
with 0, 5, 50 or 200 ng/ml of Fc-TWEAK and 0.1 or 1 µg/ml of purified antibody 
or 0.05 µg/ml of Fn14-Fc decoy. 24 h later adherent and non-adherent cells were 
harvested and incubated with Propidium Iodide (PI). Cells were analysed by flow 
cytometry and the percentage of PI positive cells (% cell death) graphed as mean 
+/-SEM, n=3. 
(F) Fn14 antibodies recognize subdomain 2 of human Fn14 extracellular domain. 
Sequence representing the extracellular domain of human Fn14 is displayed with 
the corresponding subdomains 1 and 2 below. 
 
Figure 2. Fn14 inhibition prevents tumor-induced weight loss 
(A) The C-26 cell line expresses Fn14 at high levels. Mouse tumor cell lines 
LLC and C-26 adapted to low serum (0.5% FCS) were harvested and stained 
using a commercially available anti-Fn14 antibody (ITEM1) followed by an anti-
mouse AlexaFluor-647 antibody and analyzed by flow cytometry. Black trace 
histogram: unstained cells, orange trace; secondary stain only, red trace; anti-
Fn14. 
(B) The effect of treatment with antibody 002 on C-26 tumor growth. 11 weeks-
old CD2F1 male mice were inoculated with 1x106 cells s/c in the flank (day 1). 
As tumors formed, measurements were taken and the tumor volume for each 
mouse was calculated ([length*width2]/2) and the mean and SEM for C-26 
untreated (n=5), C-26 + 002 treated (n=5) plotted. : on days 5, 12, 15 and 20 
treated mice were injected IP with 002 (10 mg/kg). A drop in average tumor 
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volume of animals treated at day 21 with antibody 002 coincides with culling of 
2 mice due to ethically prescribed limits on tumor size, as indicated in C. 
*P<0.05 vs. C-26 untreated. 
(C) Anti-Fn14 extends survival of mice bearing C-26 tumors. A Kaplan-Meier 
survival curve for the mice described in panel B. : Some 002 treated mice were 
culled because tumor size reached ethical end-point, however these mice 
nevertheless retained body weight. P<0.01 log-rank (Mantel-Cox) test. 
(D) Anti-Fn14 prevents tumor induced body weight loss. Group averages of 
mouse weight  SEM for the mice described in panel B. Weight at day 1 for 
each individual mouse =100%. Weight changes were calculated daily for each 
mouse and averaged over the total number of mice remaining in each group and 
SEM was calculated accordingly. : Some 002 treated mice culled because 
tumor size reached ethical end-point. *P<0.05 control vs. C-26 untreated; 
†P<0.05 control vs. C-26 + 002; ^P<0.05 pair-fed vs. C-26 untreated; ‡P<0.05 
C-26 untreated vs. C-26 + 002.  
 
Figure 3. Fn14 inhibition attenuates muscle wasting and weakness in C-26 
tumor-bearing mice.  
(A) CD2F1 mice were inoculated with PBS or 0.5x106 cells s/c in the flank (day 
1). : mice were injected IP with control IgG or 002 (10 mg/kg) on days 8, 12 
and 16 post inoculation. Body weight was measured daily and standardized to 
initial starting weight from day 1, and plotted as average group body weight  
SEM. Relative body mass of untreated C-26 from experiment 1 (grey, n=23) was 
significantly lower than untreated PBS (blue, n=14) from day 14 (P<0.05). Body 
mass of untreated C-26 from experiment 2 (white, n=10) was significantly lower 
than PBS and pair-fed 002 treated C-26 (red, n=10) from days 17 and 16, 
respectively (P<0.05). Body mass of pair-fed IgG treated C-26 (black, n=10) 
was significantly lower than PBS and 002 treated C-26 from days 16 and 13, 
respectively (P<0.05).   
(B) Fn14 inhibition significantly attenuates tumor induced weight loss. On day 
22 post-inoculation, tumors were surgically excised and weighed and percent 
change in tumor-free body mass compared to pre-inoculation weight calculated. 
Data represent means ± SEM. *P<0.05 vs. PBS; †P<0.05 vs. C-26 from same 
experiment; ‡P<0.05 vs. C-26 + IgG. Cross hatch (//) denotes that the data was 
obtained in two separate experiments. 
(C) Fn14 inhibition treatment prevents loss of muscle mass in tumor bearing 
mice. On day 22, selected hind limb muscles were excised and weighed. EDL; 
extensor digitorum longus, Plant; plantaris. Data are means ± SEM. *P<0.05 vs. 
PBS; †P<0.05 vs. C-26 from same experiment; ‡P<0.05 vs. C-26 + IgG. Cross 
hatch (//) denotes that the data was obtained in two separate experiments.  
(D) Fn14 inhibition treatment prevents loss of muscle mass in tumor bearing 
mice. On day 22, hearts and selected hind limb muscles were weighed. TA; 
tibialis anterior, Gastroc; gastrocnemius, Quad; quadriceps. Data are means ± 
SEM. *P<0.05 vs. PBS; †P<0.05 vs. C-26 from same experiment; ‡P<0.05 vs. 
C-26 + IgG. Cross hatch (//) denotes that the data was obtained in two separate 
experiments. 
(E) Fn14 inhibition prevents loss of adipose tissue. On day 22, epididymal fat 
was excised and weighed. Data are means ± SEM. *P<0.05 vs. PBS; †P<0.05 
vs. C-26 from same experiment; ‡P<0.05 vs. C-26 + IgG. Cross hatch (//) 
denotes that the data was obtained in two separate experiments.  
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(F) Fn14 inhibition improves body strength of tumor bearing mice. On day 21, 
whole body strength was assessed using a grip strength meter. Data are means ± 
SEM. *P<0.05 vs. PBS; †P<0.05 vs. C-26 from same experiment; ‡P<0.05 vs. 
C-26 + IgG. Cross hatch (//) denotes that the data was obtained in two separate 
experiments. 
(G) Fn14 inhibition increases peak twitch force in tumor bearing mice. On day 
22, peak twitch force of TA muscle was assessed in situ. Data are means ± SEM. 
*P<0.05 vs. PBS; †P<0.05 vs. C-26 from same experiment; ‡P<0.05 vs. C-26 + 
IgG. Cross hatch (//) denotes that the data was obtained in two separate 
experiments. 
(H) Peak tetanic force is improved in anti-Fn14 treated mice. On day 22, peak 
tetanic force of TA muscle was assessed in situ. Data are means ± SEM. 
*P<0.05 vs. PBS; †P<0.05 vs. C-26 from same experiment; ‡P<0.05 vs. C-26 + 
IgG. Cross hatch (//) denotes that the data was obtained in two separate 
experiments. 
(I) Tetanic force over a range of stimulation frequencies is improved in anti-
Fn14 treated mice. On day 22, tetanic force production at stimulation 
frequencies of 10-350 Hz was assessed in TA muscles in situ. Data are means ± 
SEM. Force from untreated C-26 from experiment 1  (grey, n=9) was 
significantly lower than untreated PBS (blue, n=7) from 30 Hz (P<0.05). Force 
from untreated C-26 from experiment 2 (white, n=9) was significantly lower 
than PBS and pair-fed 002 treated C-26 (red, n=10) from 40 Hz and 75 Hz, 
respectively (P<0.05). Force from pair-fed IgG treated C-26 (black, n=9) was 
significantly lower than PBS and 002 treated C-26 from 150-300 Hz and 100-
200 Hz, respectively (P<0.05).   
(J) Tetanic force production during fatiguing stimulation is improved in anti-
Fn14 treated mice. Tetanic force production during and following 4 minutes of 
fatiguing intermittent stimulation was assessed in TA muscles in situ. Data are 
means ± SEM. Force was lower in untreated C-26 from experiment 1 (grey, n=8) 
compared to untreated PBS (blue, n=7, P<0.001 group main effect). Force was 
lower in untreated C-26 from experiment 2 (white, n=8) and pair-fed IgG treated 
C-26 (black, n=9) compared to PBS (P<0.001 group main effect). Force was 
higher in pair-fed 002 treated C-26 (red, n=10) compared to untreated C-26 from 
experiment 2 and IgG treated C-26 (P<0.001 group main effect).   
  
Figure 4. Fn14 inhibition induces muscle fiber hypertrophy but does not 
alter muscle fiber type composition in C-26 tumor-bearing mice. 
(A) Fn14 inhibition prevents tumor-induced decrease in muscle fiber size. 
CD2F1 mice were inoculated with 0.5x106 C-26 cells s/c in the flank (day 1). 
Mice were injected IP with control IgG or 002 (10 mg/kg) on days 8, 12 and 16. 
On day 22, TA muscles were excised and frozen for histological analysis. 
Representative images of muscle cross-sections stained with hematoxylin and 
eosin (H&E) and higher magnification inset are shown. Representative H&E 
stained images for PBS controls are also shown. Scale bar = 100 µm. 
(B) Fn14 inhibition increases average muscle fiber size in C-26 tumor bearing 
mice. Muscle sections stained with anti-laminin (red, top panel, scale bar = 100 
µm) were used to quantify muscle fiber cross-sectional area (CSA, bottom 
panel). Representative laminin-stained images for PBS controls are also shown 
for comparative purposes but were not quantified due to imaging occurring on a 
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separate day. Data are means ± SEM. *P<0.05 vs. C-26; †P<0.05 vs. C-26 + 
IgG; n=8. 
(C) Representative images of muscle sections from tumor-bearing mice stained 
with anti-laminin (red), anti-myosin IIa (N2.261, green, type IIa fibers) and for 
succinate dehydrogenase activity (SDH, blue, fiber oxidative capacity). Scale bar 
= 100 µm. 
(D) Fn14 inhibition of C-26 tumor-bearing mice increases the size of both fast, 
oxidative (type IIa) and fast, glycolytic (type IIx/b) fibers but has no effect on 
their proportions in TA muscles, relative to controls. Laminin and N2.261 
staining was used to quantify cross-sectional area (CSA, top panel) and relative 
proportion (bottom panel) of type IIa and type IIx/b fibers. Data are means ± 
SEM.  *P<0.05 vs. C-26; †P<0.05 vs. C-26 + IgG; n=8. 
(E) Fn14 inhibition does not affect oxidative enzyme capacity. SDH and N2.261 
staining was used to quantify the oxidative enzyme capacity of type IIa and type 
IIx/b fibers as well as average muscle fiber oxidative enzyme capacity. Data are 
means ± SEM; n=8.  
(F) Fn14 inhibition reduced expression of ubiquitin ligases involved in muscle 
protein degradation. mRNA of MuRF-1 and atrogin-1 in TA muscles was 
quantitated and the mean value ± SEM plotted. *P<0.05 vs. PBS; †P<0.05 vs. 
C-26; ‡P<0.05 vs. C-26 + IgG; n=8-9. Cross hatch (//) denotes that the data was 
obtained in two separate experiments. 
(G) Fn14 inhibition reduced expression of the pro-inflammatory cytokines IL-6 
and TNF mRNA in TA muscles was quantitated and plotted as mean ± SEM. 
*P<0.05 vs. PBS; †P<0.05 vs. C-26; ‡P<0.05 vs. C-26 + IgG ; n=8-9. Cross 
hatch (//) denotes that the data was obtained in two separate experiments. 
 
Figure 5. Ectopic Fn14 expression in tumors causes loss of body weight and 
increases vasculature of tumors  
(A) Fn14 expression does not affect tumor volume. Female C57BL/6 mice were 
injected with 5106 tumor cells on day 1. Tumor measurements were taken and 
the tumor volume for each mouse was calculated ([length*width2]/2) and the 
mean  SEM of 3 independent experiments plotted (Fn14 n=26, Fn14-GPI n=20, 
H-Ras n=6).  
B) Fn14-positive tumors drive rapid weight loss in mice. The body weight for 
each mouse (from panel A) was assessed daily and weights standardised against 
starting weight (100%). The average for each group was calculated and graphed; 
Fn14 (red; n=26), Fn14-GPI (blue; n=20) and H-Ras V12 tumor-bearing mice 
(yellow; n=6). Error bars are SEM. 
(C) Fn14 expression increases tumor vascularity. Representative images of in 
situ tumors from mice inoculated with Fn14 expressing tumor cells (left panel) 
or Fn14-GPI expressing tumor cells (right panel). Bottom image shows 
individual tumors from Fn14 (left) and Fn14-GPI (right) resuspended in 9 ml 
PBS and disaggregated with DispaseII and collagenase A.  
(D) Fn14 expression increases tumor invasive capacity. Mice were sacrificed 
and the whole body was immediately fixed in 10% Neutral buffered Formalin. 
Tissue comprising the tumor and surrounding skeletal muscle was paraffin 
embedded, sections prepared and stained with hematoxylin and eosin. Left: 
Fn14-expressing tumor and right panel: Fn14-GPI expressing tumor, both taken 
on day 11. Images at 10 magnification (upper panel, scale bar 160 m) and 40 
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magnification (lower panel, scale bar 40 m). Blue box in 10 magnification 
represents area shown in 40 images. 
 
Figure 6. Fn14 inhibition prevents cachexia caused by Fn14 tumors 
(A) Fn14 inhibition prevents tumor induced body weight loss. Female 11 week 
old C57BL/6 mice were inoculated with a single s/c injection of mouse 
embryonic fibroblasts (MEFs) transduced with Fn14 (H-Ras V12 Fn14) or the 
parental MEF line (H-Ras V12) on day 1. Mice were given a single IP injection 
of IgG2b isotype control antibody (H-Ras V12, H-Ras V12 Fn14, n=8/group) or 
antibody 001 (H-Ras V12 Fn14+001, n=8) on day 6. Body weight was measured 
daily. 
(B) Fn14 inhibition prevents tumor induced body weight loss. On day 11, tumors 
were surgically excised and weighed allowing calculation of the percentage 
change in tumor-free body weight compared to pre-inoculation weight. Data are 
means ± SEM. *P<0.01 vs. MEF v12 Hras; †P<0.05 vs. MEF v12 Hras Fn14.  
(C) Antibody 001 prevents loss of muscle mass. On day 11, selected hind limb 
muscles were excised and weighed. EDL; extensor digitorum longus, Plant; 
plantaris, TA; tibialis anterior, Gastroc; gastrocnemius, Quad; quadriceps. Data 
are means ± SEM (n=8). *P<0.05 vs. MEF v12 Hras; †P<0.05 vs. MEF v12 
Hras Fn14. 
(D) Effect of antibody 001 on tumor induced loss of heart mass. On day 11, the 
heart from each mouse was excised and weighed. Data are means ± SEM (n=8).  
(E) Antibody 001 prevents tumor-induced loss of fat mass. On day 11, 
subscapular fat was excised and weighed. Data are means ± SEM, n=8. *P<0.05 
vs. MEF v12 Hras; †P<0.05 vs. MEF v12 Hras Fn14. 
(F) Antibody 001 attenuates the loss of tetanic force over a range of stimulation 
frequencies (left) but does not alter peak tetanic force (middle) or specific 
(normalized) force of TA muscles in situ. Data are means ± SEM, n=8. aP<0.05 
main effect MEF v12 Hras vs. MEF v12 Hras Fn14. 
(G) Tetanic force production (expressed relative to initial maximum force) 
during and after 4 min of fatiguing intermittent stimulation in TA muscles in situ 
is improved in mice treated with antibody 001. Data are means ± SEM (n=8). 
aP<0.05 main effect MEF v12 Hras vs. MEF v12 Hras Fn14, bP<0.05 main 
effect MEF v12 Hras vs. MEF v12 Hras Fn14+001, cP<0.05 main effect MEF 
v12 Hras Fn14 vs. MEF v12 Hras Fn14+001.  
(H) Antibody 001 prevents tumor induced decrease in muscle fiber size. TA 
muscles were excised and frozen. Representative images of frozen muscle 
sections stained with H&E, anti-laminin (red), anti-myosin IIa (N2.261, green) 
and for succinate dehydrogenase activity (SDH, blue) indicating muscle fiber 
architecture, individual muscle fibers, type IIa fibers and fiber oxidative 
capacity, respectively. Scale bar = 100 µm. 
(I) Laminin stained sections were used to determine average muscle fiber area. 
Data are means ± SEM, n=8. *P<0.05 vs. MEF v12 Hras; †P<0.05 vs. MEF v12 
Hras Fn14. 
(J) Treatment of mice with antibody 001 prevents tumor induced reduction in the 
size of both fast, oxidative (type IIa) and fast, glycolytic (type IIx/b) fibers in TA 
muscles.  Laminin and N2.261 stained sections were used to quantitate fiber area 
(top panel) and relative proportion (middle panel). SDH stained samples were 
used to assess the oxidative enzyme capacity of type IIa and type IIx/b fibers 
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(bottom panel). Data represent mean ± SEM (n=8). *P<0.05 vs. MEF v12 Hras; 
†P<0.05 vs. MEF v12 Hras Fn14. 
(K) Antibody 001 prevents tumor induced increase in gene expression of the 
pro-inflammatory cytokine IL-6 in TA muscles. Data are means ± SEM, n=8. 
*P<0.05 vs. MEF v12 Hras; †P<0.05 vs. MEF v12 Hras Fn14. 
 
Figure 7. Comparison of anti-cachectic activity of anti-Fn14 antibodies 
(A) Not all anti-Fn14 antibodies reverse tumor induced weight loss. Female 
C57BL/6 mice were injected with MEF H-Ras V12 Fn14 tumor cells on day 1. 
On day 7, groups of mice (n=6) were given a single IP injection of purified 
antibody 001, 002, 004 or ITEM1 (5 mg/kg: ) or no treatment. Body weight 
was measured daily and graphed as weight standardised against starting weight 
as 100. Error bars represent SEM (Groups starting at day 1 as n=6).  
(B)  Survival of mice from A graphed as a Kaplan-Meier curve.   
(C) Tumor measurements were taken and the tumor volume for each mouse was 
calculated ([length*width2]/2). Error bars  SEM. 
 
Figure 8. Host Fn14 and TWEAK are not involved in cachexia. 
(A) Groups of wildtype, Fn14-/- or Tweak-/- mice were injected with MEF H-Ras 
V12 Fn14 or Fn14-GPI tumor cells on day 1. Even numbers of male and female 
mice were used except for groups with an odd starting number. Each mouse was 
monitored for body weight and after euthanasia, tumors were removed and 
weighed and a final body mass calculated. Starting weight, final weight and final 
body mass minus tumor mass (BM-TM) are standardized to starting weight 
(100%). Mice with no tumors are shown as controls. 
(B) Group data for combined males and females for final body mass and tumor-
free body mass standardized to starting weight  (100%) from mice in panel 8A. 
*P<0.05 vs. non tumor for that strain; †P<0.05 vs. Fn14 tumor for that strain. 
(C) Muscle (TA and Quadriceps, heart) weight was assessed in all mice and 
epididymal fat was assessed in male mice. Tissue mass was standardized against 
starting body mass and averaged for each group. Error bars represent SEM. 
*P<0.05 vs. non tumor for that strain; †P<0.05 vs. Fn14 tumor for that strain. 
(D) Anti-TWEAK antibody MTW-1 blocks Tweak-induced NF-B activation. 
HEK293T cells stably infected with a lentiviral NF-B GFP reporter were 
stimulated with 0-200 ng/ml of Fc-TWEAK (grey and underlay as blue 
histogram). Cells were co-incubated with the indicated antibodies MTW-1, Rat 
IgG control or antibody 002 +/- Fc-TWEAK for 24 h. Cells were harvested and 
GFP fluorescence assessed by flow cytometry (red histogram).  
(E) Antibodies to TWEAK have no effect on cachexia. Female C57BL/6 mice 
were injected with MEF H-Ras V12 Fn14 tumor cells on day 1. On day 7, 
groups of mice (n=8) were given a single IP injection of MTW-1 antibody (anti-
Tweak, 10 mg/kg), equivalent negative control IgG antibody (Rat control; (10 
mg/kg) or antibody 002 (10 mg/kg: ) or no treatment. Body weight was 
measured daily and graphed as weight standardised against starting weight 
(100%). Error bars represent SEM (n=8).  
(F) The magnitude of wasting observed in muscles injected with AAV vectors 
expressing Activin was not affected by administration of anti-Fn14 antibodies. 
Absolute mass values for TA muscles injected with Activin-expressing AAV 
vectors (right TA muscle, RTA), or control vector (left TA muscle, LTA), as 
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harvested from mice repeatedly administered either anti-Fn14 antibodies 001 
and 002 (antibody B and A, respectively) or IgG control antibody (antibody C).  
(G) Percentage change in the mass of TA muscles injected with Activin-
expressing AAV vectors, compared with contralateral muscles receiving control 
vector, as harvested from mice repeatedly administered either anti-Fn14 
antibodies 001 and 002 or IgG control antibody.   
 
Supplementary Figure legends 
 
Supplementary Figure 1. Epitope mapping of anti-Fn14 antibodies. 
(A) Anti-Fn14 antibodies bind to Sub-domain 2 of the extracellular domain of 
Fn14. ELISAs were performed against peptides representing sub-domains 1 and 
2 of the human Fn14 extracellular domain, or control peptide. Antibodies 001, 
002, 004, commercially available antibody ITEM1, control IgG1 or IgG2b were 
assessed for binding to each peptide as indicated. Binding was detected using 
HRP-conjugated anti-mouse IgG and TMB substrate. Optical density at 450 nm 
was quantified. The IgG1 isotype control was raised against the control peptide 
and served as a positive control for the assay. 
(B) ELISAs assessing the reactivity of human Fn14 (hFn14), mouse Fn14 
(mFn14) or hFn14 single point mutants with the anti-Fn14 monoclonal 
antibodies. Data was obtained at  0.5 g/ml antibody concentration. The data for 
all antibodies tested on a single mutant was standardized against the highest 
reading. 
(C) Amino acid sequence alignment for the extracellular domains of human, 
mouse and rat Fn14. Differences to human Fn14 are underlined in the mouse and 
rat sequences. 
(D) Antibodies 001 and 002 bind efficiently to the human Fn14 H60A mutant. 
An ELISA was performed to assess binding of antibodies 001, 002, 004, 
commercial antibodies ITEM1, ITEM4 and control antibody to a recombinant 
human Fn14 H60A mutant.  
(E) Binding of 001, 002 and 004 to human Fn14 H60K mutant is distinct from 
ITEM4. An ELISA was performed to assess binding of antibodies 001, 002, 004, 
commercial antibodies ITEM1, ITEM2 and ITEM4 to a recombinant human 
Fn14 H60K mutant. 
(F) Binding of antibodies 001 and 002 is not dependent on the disulfide bond 
involving residues C57 and C66 in Fn14. A peptide representing subdomain 2 
with the 4th and 5th cysteine residues (C57 and C66) mutated to serine residues 
(Cys4&5S) was used by ELISA to assess binding of 001, 002, 004, ITEM1 and 
ITEM4.  
 
Supplementary Figure 2. Fn14 treatment reduced tumor growth rate in C-
26 tumor-bearing mice.  
CD2F1 mice were inoculated with PBS or 0.5x106 cells s/c in the flank (day 1). 
: mice were injected IP with control IgG or 002 (10 mg/kg) on days 8, 12 and 
16 post inoculation. Untreated PBS (n=7), untreated C-26 (n=9), pair-fed IgG 
treated C-26 (n=10) and pair-fed 002 treated C-26 (n=10). Tumor measurements 
(length and width) were taken daily and the tumor volume was calculated and 
graphed over time. *P<0.05 vs. C-26; †P<0.05 vs. C-26 + IgG; n=9-10 
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Supplementary Figure 3. Anti-Fn14 treatment affects tumor growth and 
body mass in the Lewis Lung Carcinoma (LLC) tumor model. Male 
C57BL/6 mice were given a single s/c injection of LLC cells or PBS on day 1. 
: mice were treated with IP injection of: IgG2b isotype control antibody (PBS + 
IgG and LLC + IgG, n=8/group) or 002 (PBS + 002 and LLC + 002, n=8) on 
days 7, 14, 21 and 28, and were sacrificed on day 35.  
(A) Tumor measurements were taken daily and graphed as group averages. Data 
are means ± SEM. aP<0.01 main effect LLC + IgG vs. LLC + 002. 
(B) On day 35, the tumor was surgically excised, weighed and group averages 
calculated and graphed for tumor volume. Data are means ± SEM. *P<0.03 vs. 
LLC + IgG. 
(C) Body weight for the PBS groups was measured daily and graphed as group 
average body weight standardised against starting weight (100%). Data are 
means ±SEM. 
(D) Body weight for the LLC groups was measured daily and graphed as group 
average body weight standardised against starting weight (100%). Data are 
means ±SEM.  aP<0.01 main effect LLC + IgG vs. LLC + 002. 
 
Supplementary Figure 4. Anti-Fn14 treatment does not decrease tumor size 
in mice carrying a MEF v12 Hras Fn14 tumor. Female 11 weeks-old 
C57BL/6 mice were inoculated with a single s/c injection of mouse embryonic 
fibroblasts (MEFs) transduced with Fn14 (v12 Hras Fn14) or the parental MEF 
line (v12 Hras) on day 1. Mice were given a single IP injection of IgG2b isotype 
control antibody (v12 Hras, v12 Hras Fn14, n=8/group) or 001 (v12 Hras 
Fn14+001, n=8) on day 6. On day 11, the tumor was surgically excised, weighed 
and group averages calculated and graphed for tumor mass and volume. Data are 
means ± SEM.  
  
Supplementary Figure 5. Commercially available Fn14 antibody ITEM1 
does not inhibit TWEAK/Fn14-induced NF-κB. HEK293T cells stably 
infected with a lentiviral NF-B GFP reporter were stimulated with or without 
Fc-TWEAK 100 ng/ml. Purified antibodies IgG control (top panels; grey 
histograms), 001 or ITEM1 (100 ng/ml) were co-incubated with TWEAK for 24 
hours and the cells harvested and GFP fluorescence assessed by flow cytometry 
(red histograms, compare to IgG control grey overlay). 
 
Supplementary Figure 6. Effect of antibody treatment on reversal of 
cachexia. 
(A) Anti-Fn14 antibodies 001 and 002 reversed tumor induced weight loss. 
Female C57BL/6 mice were innoculated on day 1 with MEF tumor cells 
expressing Fn14 or Fn14-GPI. On day 8 (after initial weight loss), groups of 
mice (n=3) were given a single IP injection of purified antibody (5 mg/kg: ) or 
no treatment. Body weight was measured daily and graphed as weight 
standardized against starting weight (100%). Error bars represent SEM (Groups 
starting at day 1 as n=3).  
(B)  Survival of mice from A, graphed as a Kaplan-Meier curve.   
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Supplementary Figure 7. Correlation between expression of Fn14 and 
cytokine mRNA in various cancer types.   
The correlation between transcript levels of Fn14 and (A) IL-1, (B) IL-1, (C) 
IL-6, (D) IL-8 and (E) TNF are depicted for Breast (n=988), Head and Neck 
(n=303), Lung (n=482), Colorectal (n=316) and Stomach (n=273) cancers.   
Benjamini & Hochberg (1995) adjusted P-values calculated to measure 
statistical significance of observed correlations.  
(F) Summary of Fn14 correlation with cytokines in different cancer types. 
Correlation coefficients that are statistical significant at Benjamini & Hochberg 
(1995) adjusted P-value < 0.05 are highlighted by (*). 
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IL-1 0.19* 0.46* 0.50* 0.00 0.21
IL-1 0.17* 0.23 0.42* 0.09 0.11
IL-6 0.21* 0.21 0.20* 0.19 0.08
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TNF 0.15* 0.14 0.35* 0.17 0.18
Pearson Correlation Coefficients for expression of Fn14 with cytokines in human cancers
